Ionis Pharmaceuticals (IONS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbers are better ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) HALOS Study of ION582 in Angelman Syndrome Conference Call July 22, 2024 8:00 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Holly Kordasiewicz - Senior Vice President, Neurology Elizabeth Jalazo - Assistant Professor of Pediatrics, Division of Genetics & Metabolism, University of North Carolina School of Medicine Becky Crean - Executive Director, Neurology Lynne Bird - Professor of Clinical ...

Loading... Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS). AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide. The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor f ...

ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from parents and clinicians 97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms as measured by the SAS-CGI-C Improvements on the Bayley-4 in cognition, communication and motor function exceeded those observed in natural history studies Ionis plans to initiate Phas ...

Though IONS did not specify the total number of patients enrolled in the study, a government website states that the study has a target enrolment of nearly 73 study participants aged between two to 65 with AxD across eight countries. AxD is a rare neurological disease that affects a type of cell in the brain called astrocytes, which have multiple roles in the brain to support neurons and oligodendrocytes. People living with this condition are marked by cognitive dysfunction and progressive neurologic deteri ...

CARLSBAD, Calif., July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, August 1st at 11:30 a.m. Eastern Time to discuss its second quarter 2024 financial results. About Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D. – [email protected] – 760-603-2331 SOURCE Ionis Pharmaceuticals, Inc. Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time The webcast may be accessed at htt ...

Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition AxD is estimated to occur in an estimated one in one million people in the U.S. and can present throughout life.1-3 The disease is a result of genetic variants in the glial fibrillary acidic protein (GFAP) gene that disrupt the structure and function of astrocytes in the brain. AxD is generally characterized by cognitive dysfunction and progressive neur ...

CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio. About Ionis Pharmaceuticals, Inc ...

Image Source: Zacks Investment Research Olezarsen is one of Ionis' wholly-owned pipeline candidates, which it intends to launch independently in the United States. The drug's commercial launch is part of management's broad strategy to deliver a steady flow of wholly-owned medicines to patients. If approved, the drug will not only be Ionis' first independent product launch but also the first FDA-approved treatment for FCS. Last month, Ionis reported positive data from two phase III studies — OASIS-HAE and OA ...

– Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – CARLSBAD, Calif., June 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS) ...